Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LP-184 by Lantern Pharma for Bladder Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...
LP-184 by Lantern Pharma for Colorectal Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
LP-184 by Lantern Pharma for Prostate Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...
LP-184 by Lantern Pharma for Ovarian Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
LP-184 by Lantern Pharma for Lung Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Lung Cancer. According to GlobalData, Phase...
LP-184 by Lantern Pharma for Pancreatic Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
LP-184 by Starlight Therapeutics for Central Nervous System (CNS) Cancer: Likelihood of Approval
LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Central Nervous System (CNS) Cancer. According...
LP-184 by Lantern Pharma for Liver Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Liver Cancer. According to GlobalData, Phase...
LP-184 by Lantern Pharma for Pancreatic Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
LP-184 by Lantern Pharma for Melanoma: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Melanoma. According to GlobalData, Phase I...
LP-184 by Lantern Pharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
LP-184 by Lantern Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Non-Small Cell Lung Cancer. According to...
LP-184 by Lantern Pharma for Glioblastoma Multiforme (GBM): Likelihood of Approval
LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
LP-184 by Starlight Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
LP-184 by Starlight Therapeutics for High-Grade Glioma: Likelihood of Approval
LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...